Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.67 |
| ▸ | DRD3 | P35462 | 11/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28728225 | 0.93 | DRD2 (0.59) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL31523251 | 0.92 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL14102178 | 0.91 | DRD2 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL13197442 | 0.91 | DRD3 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL28306714 | 0.91 | DRD3 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL4673932 | 0.91 | DRD2 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL13197443 | 0.91 | DRD3 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL2227921 | 0.90 | DRD2 (0.71) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL4071635 | 0.89 | DRD2 (0.59) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL30809964 | 0.89 | DRD2 (0.69) | DRD2DRD3CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118390073-A | Organic electrochemical synthesis method of cyclopropane compound | 南京林业大学 | 2024-07-26 | — | — | CN | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112341399-A | 1,2, 4-triazole derivative compounds and application thereof in treating inflammatory bowel diseases | 王健 | 2021-02-09 | — | — | CN | disclosed |
| CN-102753533-A | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LTD | 2012-10-24 | — | — | CN | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| CN-101103008-A | Macrocyclic compounds useful as bace inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | DRD2 3124/4885DRD3 3013/4885CYP2D6 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.